ES2502366T3 - Inducción de inmunidad tumoral por variantes de proteína de unión a folato - Google Patents

Inducción de inmunidad tumoral por variantes de proteína de unión a folato Download PDF

Info

Publication number
ES2502366T3
ES2502366T3 ES11004714.9T ES11004714T ES2502366T3 ES 2502366 T3 ES2502366 T3 ES 2502366T3 ES 11004714 T ES11004714 T ES 11004714T ES 2502366 T3 ES2502366 T3 ES 2502366T3
Authority
ES
Spain
Prior art keywords
binding protein
folate
induction
tumor immunity
protein variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES11004714.9T
Other languages
English (en)
Inventor
Constantin G. Ioannides
George E. Peoples
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
University of Texas at Austin
Original Assignee
University of Texas System
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, Henry M Jackson Foundation for Advancedment of Military Medicine Inc, University of Texas at Austin filed Critical University of Texas System
Application granted granted Critical
Publication of ES2502366T3 publication Critical patent/ES2502366T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/155Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17Newcastle disease virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un antígeno que comprende un epítope de proteína de unión a folato de SEC ID Nº: 2, SEC ID Nº: 3, SEC ID Nº: 4, SEC ID Nº: 5, SEC ID Nº: 6, SEC ID Nº: 7, SEC ID Nº: 8, o una combinación de las mismas.

Description

Inducción de inmunidad tumoral por variantes de proteína de unión a folato
DESCRIPCIÓN
A
ES11004714.9T 2001-03-09 2002-03-08 Inducción de inmunidad tumoral por variantes de proteína de unión a folato Expired - Lifetime ES2502366T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27467601P 2001-03-09 2001-03-09
US274676P 2001-03-09

Publications (1)

Publication Number Publication Date
ES2502366T3 true ES2502366T3 (es) 2014-10-03

Family

ID=23049174

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11004714.9T Expired - Lifetime ES2502366T3 (es) 2001-03-09 2002-03-08 Inducción de inmunidad tumoral por variantes de proteína de unión a folato

Country Status (9)

Country Link
US (5) US7547759B2 (es)
EP (2) EP1472337A4 (es)
JP (3) JP4401075B2 (es)
CA (1) CA2440610C (es)
DK (1) DK2371854T3 (es)
ES (1) ES2502366T3 (es)
PT (1) PT2371854E (es)
SI (1) SI2371854T1 (es)
WO (1) WO2002072766A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2371854T1 (sl) * 2001-03-09 2014-09-30 Board Of Regents, The University Of Texas System Office Of The General Counsel Induciranje imunosti tumorja z variantami beljakovine, ki se veĺ˝e na folat
JP2008533114A (ja) * 2005-03-18 2008-08-21 ユーシーエル ビジネス パブリック リミテッド カンパニー メカノ成長因子ペプチドおよびその使用
US8133691B2 (en) 2005-07-06 2012-03-13 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Stable quantitation and detection of immune response levels with non-zero background peptides
JP5164167B2 (ja) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体25(tnfr25)のアゴニスト、アンタゴニスト及び免疫毒素
US8486412B2 (en) 2006-06-01 2013-07-16 Mayo Foundation For Medical Education And Research Immunity to folate receptors
US9993538B2 (en) 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors
MA45169A (fr) 2016-05-31 2019-04-10 Sellas Life Sciences Group Inc Thérapie vaccinale pour le traitement du cancer de l'endomètre et de l'ovaire
EP3290395A1 (en) * 2016-09-02 2018-03-07 Paques I.P. B.V. Anaerobic purification device with variable water column
CN110662839A (zh) * 2017-02-17 2020-01-07 珀杜研究基金会 用于细胞疗法的基于靶向性配体-有效负载的药物递送

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826364A (en) 1972-05-22 1974-07-30 Univ Leland Stanford Junior Particle sorting method and apparatus
US4284412A (en) 1979-07-13 1981-08-18 Ortho Diagnostics, Inc. Method and apparatus for automated identification and enumeration of specified blood cell subclasses
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
US4498766A (en) 1982-03-25 1985-02-12 Becton, Dickinson And Company Light beam focal spot elongation in flow cytometry devices
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US6514942B1 (en) * 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5830755A (en) 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
DE69726404T2 (de) * 1996-01-05 2004-09-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Mesothelinantigen, verfahren und testsatz zur targetierung
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
EP2848255B1 (en) * 2001-02-20 2017-08-23 Janssen Pharmaceuticals, Inc. Artificial Drosophila antigen presenting cell for preparing CD8 cell suspension for use in the treatment of cancer
SI2371854T1 (sl) * 2001-03-09 2014-09-30 Board Of Regents, The University Of Texas System Office Of The General Counsel Induciranje imunosti tumorja z variantami beljakovine, ki se veĺ˝e na folat
US9993538B2 (en) * 2015-05-29 2018-06-12 Galena Biopharma, Inc. Peptide vaccine therapy for treatment of FRα-expressing tumors

Also Published As

Publication number Publication date
WO2002072766A2 (en) 2002-09-19
JP2004532825A (ja) 2004-10-28
DK2371854T3 (da) 2014-08-11
US20130039935A1 (en) 2013-02-14
EP2371854B1 (en) 2014-05-07
CA2440610C (en) 2011-07-12
US8258261B2 (en) 2012-09-04
SI2371854T1 (sl) 2014-09-30
EP1472337A4 (en) 2008-02-27
JP2009114190A (ja) 2009-05-28
EP2371854A2 (en) 2011-10-05
EP2371854A3 (en) 2011-12-21
EP1472337A1 (en) 2004-11-03
US20180194806A1 (en) 2018-07-12
JP5017238B2 (ja) 2012-09-05
US20030185840A1 (en) 2003-10-02
CA2440610A1 (en) 2002-09-19
US8815256B2 (en) 2014-08-26
US7547759B2 (en) 2009-06-16
US20150175658A1 (en) 2015-06-25
PT2371854E (pt) 2014-08-25
JP4401075B2 (ja) 2010-01-20
US9562070B2 (en) 2017-02-07
WO2002072766A8 (en) 2004-09-02
US20090227510A1 (en) 2009-09-10
JP2012097111A (ja) 2012-05-24

Similar Documents

Publication Publication Date Title
ATE542829T1 (de) Impfstoff
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
NO20041917D0 (no) Spesifikke midler som binder humant angiopoietin-2
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
DK1362109T3 (da) Rekombinante oligomere protein-komplekser med foröget immunogent potentiale
PT1557462E (pt) Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização
NO20025838D0 (no) Antigene polypeptider
YU68002A (sh) Modifikovani faktor viii
ATE378403T1 (de) Transchromosomale transgen-nagetiere zur herstellung von humänen antikörpern
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
WO2004030608A3 (en) Nanoemulsion vaccines
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
CY1114614T1 (el) Αντιγονα αιμοφιλου ινφλουεντσας και αντιστοιχα dna θραυσματα
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
CY1107784T1 (el) Πρωτεϊνη συντηξης g του ihnv για διεγερση του ανοσοποιητικου συστηματος
DE60224667D1 (de) Perylenequinonen zur anwendung als sonosensitizer
MXPA02012857A (es) Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
DE50204475D1 (de) Präparationen von vitamin e in kombination mit afamin
BR0111785A (pt) Composições e métodos para tratamento de candidìase
CY1106200T1 (el) Αντισωματα εναντια σε κασπαση-8, παρασκευη και χρηση τους
EP1454914A4 (en) TUMOR ANTIGEN
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
GB0409559D0 (en) Polypeptide